Table 3. Best overall response.

Response, n (%)	Nilotinib 400 mg bid n=18	Nilotinib 200 mg qd/imatinib 400 mg bid n=7	Nilotinib 400 mg qd/imatinib 400 mg bid n=7	Nilotinib 400 mg bid/imatinib 400 mg bid n=5	Nilotinib 400 mg bid/imatinib 400 mg qd n=16
Complete response	0	0	0	0	0
Partial response	1 (6)	0	0	0	1 (6)
Stable disease	13 (72)	7 (100)	5 (71)	4 (80)	9 (56)
Progressive disease	2 (11)	0	1 (14)	0	6 (38)
Unknown*	1 (6)	0	0	0	0
N/A†	1 (6)	0	1 (14)	1 (20)	0
Progression-free survival – Kaplan-Meier estimates
Rate at 4 months, %	59	83	43	50	56
Rate at 6 months, %	47	17	29	50	56
Median, days	168	143	112	Ongoing	Ongoing
Range	1-393	56-223	22-336	1-322	27-180
Median follow-up, days	186	153	113	167	126

^*Best response could not be classified as partial or complete response, progressive or stable disease;

^†Not assessed: patients had discontinued study prior to the first post-baseline tumor assessment.